- Home
- EVN vs TRVI Comparison
EVN vs TRVI Comparison
Compare EVN & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVN
- TRVI
- Stock Information
- Founded
- EVN 1998
- TRVI 2011
- Country
- EVN United States
- TRVI United States
- Employees
- EVN N/A
- TRVI N/A
- Industry
- EVN Investment Bankers/Brokers/Service
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- EVN Finance
- TRVI Health Care
- Exchange
- EVN Nasdaq
- TRVI Nasdaq
- Market Cap
- EVN 398.3M
- TRVI 341.4M
- IPO Year
- EVN N/A
- TRVI 2019
- Fundamental
- Price
- EVN $10.35
- TRVI $3.56
- Analyst Decision
- EVN
- TRVI Strong Buy
- Analyst Count
- EVN 0
- TRVI 8
- Target Price
- EVN N/A
- TRVI $9.31
- AVG Volume (30 Days)
- EVN 101.2K
- TRVI 659.4K
- Earning Date
- EVN 01-01-0001
- TRVI 03-19-2025
- Dividend Yield
- EVN 4.78%
- TRVI N/A
- EPS Growth
- EVN N/A
- TRVI N/A
- EPS
- EVN 0.34
- TRVI N/A
- Revenue
- EVN N/A
- TRVI N/A
- Revenue This Year
- EVN N/A
- TRVI N/A
- Revenue Next Year
- EVN N/A
- TRVI N/A
- P/E Ratio
- EVN $29.94
- TRVI N/A
- Revenue Growth
- EVN N/A
- TRVI N/A
- 52 Week Low
- EVN $8.64
- TRVI $1.30
- 52 Week High
- EVN $10.45
- TRVI $4.68
- Technical
- Relative Strength Index (RSI)
- EVN 58.31
- TRVI 43.13
- Support Level
- EVN $10.12
- TRVI $3.63
- Resistance Level
- EVN $10.23
- TRVI $4.06
- Average True Range (ATR)
- EVN 0.11
- TRVI 0.30
- MACD
- EVN 0.05
- TRVI -0.11
- Stochastic Oscillator
- EVN 95.74
- TRVI 0.44
About EVN Eaton Vance Municipal Income Trust
Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.